Egetis Therapeutics & Anovo Unite for MCT8 Patients
January 2, 2024
Egetis Therapeutics is an innovative pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment.
What is MCT8 Deficiency (Allan-Herndon-Dudley Syndrome)?
MCT8 deficiency, a rare and debilitating disorder also known as Allan-Herndon-Dudley Syndrome, poses significant challenges for affected individuals and their loved ones. This genetic condition primarily affects brain development and function, leading to developmental delays, muscle weakness, and neurological impairments. Despite its rarity, the impact of Allan-Herndon-Dudley Syndrome is profound, underscoring the urgent need for effective treatments and interventions to improve the quality of life for those affected.
Egetis Therapeutics Partners with Anovo
At Anovo, we’re proud to work with Egetis Therapeutics to help more patients access their innovative new therapy for MCT8 deficiency. Since there is currently no available approved treatment for MCT8 deficiency, our partnership enables us to administer the Egetis Early Access Program (EAP), providing hope and support to patients and families facing the challenges of MCT8 deficiency. Together, we’re committed to advancing the field of rare disease treatment, working towards a brighter future for our patients and their caregivers.
Related Posts
Nationwide Coverage: Anovo Geographic Reach and Service Consistency
True nationwide specialty pharmacy coverage requires comprehensive infrastructure, robust logistics partnerships, and operational systems designed to overcome geographic challenges. At…
October 24, 2025
Business Continuity Planning: Anovo’s Redundancy and Disaster Recovery
When patients depend on life-changing rare disease therapies, service interruptions can have devastating health consequences. At Anovo, our business continuity…
September 8, 2025
Behind the Delivery: How Anovo’s 3PL/Wholesale Team Keeps Rare Therapies Moving
At Anovo, every team plays a role in delivering hope to patients living with rare diseases. While many think of…
August 20, 2025